Across TCGA pan-cancer cohorts, PGBD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PGBD2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PGBD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PGBD2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LSCC, and LUAD are the cancer types where PGBD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.708	0.316	.004	12	view →
LSCC	OS	Median	All	0.933	0.614	.008	10	view →
LUAD	DFS	Median	II,III,IV	0.197	1.000	.014	6	view →
UCEC	DFS	Quartile	All	0.761	1.000	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PGBD2 tumor-vs-normal RNA expression · all PGBD2 data types